查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1830371

基因组编辑市场（按技术、应用、最终用户、治疗领域和交付方式）—2025-2032 年全球预测

Genome Editing Market by Technology, Application, End User, Therapeutic Area, Delivery Method - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年基因组编辑市场规模将达到 5,434.6 亿美元，复合年增长率为 54.73%。

主要市场统计数据
基准年2024年 165.4亿美元
预计2025年 257.8亿美元
预测年份：2032年 5434.6亿美元
复合年增长率（%） 54.73%

对基因组编辑生态系统转型的简明而权威的定位，将科学进步与营运和政策现实结合

基因组编辑已从实验室的一项小众技术发展成为现代生命科学的核心支柱，改变了研究范式、治疗方法的开发和农业创新。过去十年，精准编辑化学和递送系统的进步，提高了攻克先前难以攻克的基因标靶的可行性。因此，转化研究管道已扩展至基因校正、细胞工程以及作物和牲畜的性状改良，而工业生产也开始利用基因编辑生物体进行更高价值的生物製造。

因此，如今的生态系统涵盖了学术实验室、合约研究组织、生物技术公司和大型製药公司。每个相关人员需要差异化的证据：研究人员需要实验室级检验，产业需要可扩展的生产方法，商业开发需要监管和报销资讯。因此，整合技术能力、特定应用的限制和监管环境对于做出明智的决策至关重要。

此外，地缘政治和贸易动态为供应链和资本配置带来了新的变数。这些外部压力与技术进步相互作用，影响基因组编辑创新的开发、测试和商业化的地点和方式。因此，读者应该期待一份全面的评估，将科学发展轨迹与政策变化以及与市场相关的营运考量联繫起来。

深入综合科学、监管和营运方面的变化，重新定义基因组编辑领域的优先事项和价值创造

基因组编辑领域正在经历多重变革，这些变革正在重塑研究重点和商业策略。首先，编辑平台精度和安全性的提升正在改变治疗和农业应用的风险效益计算，推动研究从发现研究转向转化研究和临床研究。这种转变凸显了递送技术和有效载荷优化作为提升临床可行性的关键因素的重要性。

其次，编辑系统的模组化和互通性正在加速创新週期。碱基编辑器、Prime 编辑器和 CRISPR 特异性核酸酶等平台可以与不断发展的递送载体结合，创造出针对不同目标的解决方案，从而使更广泛的相关人员能够追求差异化的价值提案。因此，我们看到分子生物学家、递送专家和製程工程师之间的跨学科合作日益增多。

第三，法律规范正在不断调整，世界各地的机构正在改善其关于安全性评估、脱靶评估和长期追踪要求的指导。这些监管细化正在影响研发时间表和所需证据，同时也为研发机构和监管机构之间更早的对话铺平了道路。同时，社会和投资者日益严格的审查也使得透明的安全数据和强大的患者参与策略变得尤为重要。

最后，宏观经济和贸易因素促使企业重新评估其供应链、试剂采购和生产布局。为此，企业正在多元化供应商关係，并投资于区域能力建设，以减少外部衝击的影响。总而言之，这些转变需要企业制定灵活的策略，将科学的愿景与务实的产业计画结合。

对 2025 年关税如何改变整个基因组编辑价值链的供应链、筹资策略和营运决策的批判性分析

关税制度和跨境贸易的政策变化对基因组编辑生态系统有重大影响，会影响试剂流通、设备进口和下游製造成本基础。 2025年征收的累积关税强化了供应链韧性和供应商多元化的重要性，因为企业在酶、核酸合成服务和专用实验室设备等关键投入方面面临更长的前置作业时间和更高的累积成本。

因此，各公司加快了在地化进程，并寻求具备区域能力的替代供应商。同时，采购团队采取了多方采购策略和长期合同，以稳定供应和价格风险。这些调整影响了计划排序和资本配置决策，尤其对于那些临床研发管线时间紧迫的公司。

此外，关税主导的成本压力改变了仪器和试剂製造商与其下游客户之间的谈判动态。为了保持竞争力，一些供应商透过提供配套服务、灵活资金筹措或在岸组装选项来应对。从策略角度来看，这些发展增强了垂直整合模式和内部製造能力对寻求控制关键製造流程的大型机构的吸引力。

此外，关税的影响因应用程式和最终用户而异，学术机构和小型开发商通常比资金雄厚的製药公司更容易受到直接成本上涨的影响。因此，联合采购共用和共享核心设施已成为切实可行的应对措施，使多个组织能够分摊固定成本，并在关税相关干扰的情况下保持对关键技术的获取。

策略性细分框架，细分技术、应用、最终用户、治疗领域和交付方法，以确定可行的计划和投资影响

细分市场提供了将科学细微差别转化为商业性洞察所需的分析框架。按技术细分，市场包括碱基编辑，包括腺嘌呤和胞嘧啶碱基编辑亚型；CRISPR系统进一步细分为Cas12、Cas13和Cas9变体；prime编辑；Megatal、TALEN和ZFN，每种技术在精度、有效载荷限制和脱靶率方面都呈现出不同的技术权衡。这种细分至关重要，因为平台属性决定了下游在递送、标靶选择和安全测试方面的选择，从而影响可行的适应症类型和方案设计。

按应用分类，主要发展轨迹涵盖以作物和牲畜改良为重点的农业应用、生质燃料和生物製造等工业生物技术用例、涵盖基础研究和药物发现的研究应用，以及包括细胞和基因治疗在内的治疗应用。这些应用领域需要不同的依证，农业和工业优先考虑性状稳定性和规模化，而治疗开发者则强调临床安全性、有效性和监管合规性。

就最终用户而言，生态系统涵盖学术研究机构、合约研究组织和製药/生物技术公司，每个公司都有不同的营运模式、资金週期和扩大规模的能力：学术中心通常充当创新中心和早期概念验证的生成器，CRO 提供专业知识和可扩展的执行，而製药/生物技术公司则专注于商业开发和监管途径。

治疗领域细分可识别出生物复杂性、患者群体和临床试验设计考量差异显着的优先领域，例如循环系统、遗传疾病、感染疾病、神经病学和肿瘤学。递送方法细分则进一步明确了可行性。电穿孔和脂质奈米颗粒等非病毒方法可提供瞬时表现图谱并降低免疫抗原性风险，基因枪和显微注射等物理方法可实现体外操作和局部递送，而病毒载体策略对于持续体内表达至关重要。了解这些细分视角如何交织，有助于相关人员根据目标适应症和开发策略调整平台选择。

区域比较分析揭示了不同的法规环境、製造能力和研究生态系统如何影响全球市场的基因组编辑策略

区域动态对技术应用、监管策略和伙伴关係模式具有决定性的影响。在美洲，强劲的创业投资活动、集中的临床试验基础设施以及密集的转化研究中心网络，支持着新型编辑疗法从发现到早期临床开发的快速发展。这些区域优势使美洲成为加速转化势头的合作科学网路和大型生物技术丛集的中心。

跨多个司法管辖区的监管协调以及多元化的支付方格局正在塑造欧洲、中东和非洲地区（EMEA）的研发策略。欧洲研究机构持续为基础科学进步做出贡献，而新兴企业和大型製药公司则需应对复杂的报销和伦理框架。同时，对生产能力的投资和策略性官民合作关係正成为维持先进疗法竞争力的途径。

亚太地区正在拓展其研究和商业化途径，其生产能力迅速提升，技术精湛的科学家数量不断增加，政府也积极支持生物技术创新。此外，由于地区间监管时限和临床试验入组动态的差异，跨国研发公司正在采取灵活的临床策略，利用该地区的优势，加快患者招募速度，并实现经济高效的研发。

在全部区域，相关人员越来越多地采用混合策略，将本地能力与跨境伙伴关係相结合，以优化人才、资本和患者群体的获取，同时管理区域监管和供应链差异。

我们清楚检验推动平台创新者、治疗开发商、服务供应商、製造专家等竞争定位的策略。

基因组编辑领域的公司层面动态反映了一系列原型，从平台技术先驱到垂直整合开发商，再到专业服务供应商。以平台为中心的公司专注于提高编辑特异性、扩大标靶覆盖范围，并建立可授权或合作用于各种应用的模组化系统。这些公司通常在研发方面投入巨资，并在碱基编辑、主要编辑和核酸酶优化等核心技术领域中保持主导地位。

治疗开发公司通常采用许可和合作的方式，将其平台优势与临床和监管专业知识相结合，以加速将早期发现转化为临床候选药物。服务供应商和合约委外研发机构正在透过捆绑端到端功能（包括标靶验证、交付优化和符合GLP的安全性测试）来适应这一趋势，为希望外包技术复杂性的赞助商提供承包解决方案。

製造和供应链专业人员也在不断发展，透过投资可扩展的填充、载体生产和品质系统来支持先进疗法的生产。此外，他们也越来越重视策略伙伴关係，将平台所有者与製造专家和商业合作伙伴联繫起来，以降低后期开发风险并扩大市场准入。总而言之，这些企业级策略展现了生态系统参与者如何定位自身，以便在从创新到商业化的不同阶段中获得价值。

为高阶主管提供以行动为导向的策略指导，帮助他们协调技术开发、伙伴关係、监管参与和营运弹性，实现永续成长

产业领导者必须采取多管齐下的务实策略，将技术前景转化为商业性成功。首先，对递送创新和有效载荷工程的投资至关重要，因为改进编辑系统到达目标细胞和组织的方式将对临床可行性和农业应用成果产生重大影响。公司应在专案设计早期优先整合编辑化学和递送方法，以降低下游开发风险。

其次，领导者应寻求灵活的合作模式，在独立控制与合作研究的实际效益之间取得平衡。与专业的委外研发机构、生产合作伙伴和区域开发中心建立策略联盟，可以加快临床试验的进度，同时保留商业化选择。同时，培养强大的监管能力，并在开发早期与监管机构合作，可以铺平核准之路，并明确可接受的安全终点。

第三，上市公司必须透过供应链多元化、区域生产计画和长期供应商协议来增强营运韧性。这些措施将减轻贸易中断带来的风险，并确保临床和商业项目的连续性。此外，上市公司应加强其资料管治和道德监督框架，以维护公众信任并满足不断变化的社会期望。

最后，公司应基于清晰的市场进入策略来制定投资决策，该策略应考虑治疗领域的复杂性、患者招募动态和报销方案。将平台优势与兼具科学合理性、监管可行性和商业性潜力的适应症相匹配，使领导者能够优先考虑未来影响最大、资源效率最高的项目。

透明而严谨的混合方法研究途径结合了专家访谈、技术文献综合和基于场景的分析，检验了研究结果

调查方法结合了定性方法以及来自一手和二手研究的严格证据整合，旨在为基因组编辑生态系统提供坚实的洞见。一手研究包括与来自学术机构、受託研究机构、生物技术开发公司和疗法申办方的主题专家进行结构化访谈。这些访谈提供了关于实际限制、发展时间表和策略重点的背景信息，而这些资讯在一般文献中并不常见。

我们的二手资料研究综合了同行评审的出版物、监管指南文件、专利申请和企业资料披露信息，构建了全面的技术和政策叙述。在适当的情况下，我们查阅了技术白皮书、会议论文集和预印本文献，以了解编辑平台和交付系统的最新进展。对这些资讯来源的三角检验确保了我们的结论是基于可重复的证据和同行检验。

本研究采用的分析架构包括技术就绪评估、价值链映射和基于情境的风险分析。透过迭代同侪审查进行敏感度检查，并透过跨部门研讨会检验研究结果，以确保研究结果与研发和商业相关人员相关者的相关性。主要访谈内容均采取保密措施，以保护个人独特意见并鼓励坦诚评论。

将技术创新与监管、道德和营运要求相结合的简明综合体，以指导决策者制定有影响力的计划

基因组编辑的发展轨迹体现了许多因素的汇聚：编辑化学技术的精进、交付方式的成熟、监管预期的演变以及经济压力的变化。这些因素共同创造了一个充满活力的环境，其中策略敏捷性、技术力和营运稳健性将决定哪些专案能够成功地从概念转化为实际影响。要驾驭这种环境，相关人员需要在平台重点、伙伴关係结构和地理部署方面做出审慎的选择。

重要的是，无论是在治疗、农业或工业生物技术领域，短期内最有前景的机会是那些将技术可行性与清晰的转化途径结合的机会。同时，管理供应链风险以及投资合规和道德管治对于维持长期发展动能至关重要。综合考虑技术、监管和商业性因素，组织能够优先考虑最有可能带来有意义的科学和社会效益的努力。

最终，基因组编辑的成功不仅取决于科学突破，还取决于组织负责任、有弹性地大规模实施这些突破的能力。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 碱基编辑和主要编辑技术的进步，可实现精确的单碱基修改
  • 整合人工智慧驱动的生物资讯平台来指导 CRISPR 标靶选择
  • 用于体内治疗的非病毒递送系统的开发
  • 协调监管努力，推动基因编辑疗法获得全球核准
  • 围绕生殖系应用的伦理和社会问题
  • 扩大 CRISPR 诊断技术，用于快速检测和监测感染疾病
  • 将基因编辑细胞疗法商业化用于治疗血液疾病和癌症
  • 开展昆虫基因驱动计划，用于媒介传播疾病控制和生态学风险评估
  • 抗CRISPR蛋白作为基因组编辑通讯协定中的安全开关的出现
  • 多重基因组编辑技术在细胞内建构复杂基因迴路的进展
  • 生物製药公司与科技公司之间的策略合作加速研究
  • 最高法院最近就 CRISPR 智慧财产权做出裁决后，专利格局正在改变

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章 基因组编辑市场（按技术）

  • 碱基编辑
    • 腺嘌呤碱基编辑
    • 胞嘧啶碱基编辑
  • CRISPR
    • Cas12
    • Cas13
    • Cas9
  • 巨型行星
  • Prime Edit
  • 塔伦
  • Zfn

第九章 基因组编辑市场（按应用）

  • 农业
    • 作物改良
    • 牲畜改良
  • 工业生物技术
    • 生质燃料
    • 生物製造
  • 研究
    • 基础研究
    • 药物研发
  • 治疗药物
    • 细胞疗法
    • 基因治疗

第 10 章 基因组编辑市场（依最终使用者划分）

  • 学术机构
  • 合约研究组织
  • 製药生物技术

第 11 章 基因组编辑市场（依治疗领域）

  • 心臟病学
  • 遗传性疾病
  • 感染疾病
  • 神经病学
  • 肿瘤学

第 12 章。按交付方式分類的基因组编辑市场

  • 非病毒
    • 电穿孔
    • 脂质奈米颗粒
  • 物理方法
    • 基因枪
    • 显微注射
  • 病毒载体

第十三章 基因组编辑市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 基因组编辑市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章 各国基因组编辑市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Merck KGaA
    • Agilent Technologies, Inc.
    • Lonza Group AG
    • Sartorius AG
    • Becton Dickinson and Company
    • CRISPR Therapeutics AG
    • Intellia Therapeutics, Inc.
    • Sangamo Therapeutics, Inc.
Product Code: MRR-431C35F6C15D

The Genome Editing Market is projected to grow by USD 543.46 billion at a CAGR of 54.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 16.54 billion
Estimated Year [2025] USD 25.78 billion
Forecast Year [2032] USD 543.46 billion
CAGR (%) 54.73%

A concise and authoritative orientation to the transforming genome editing ecosystem that integrates scientific advances with operational and policy realities

Genome editing has evolved from a niche laboratory capability into a central pillar of modern life sciences, transforming research paradigms, therapeutic development, and agricultural innovation. Over the past decade, advances in precision editing chemistries and delivery systems have increased the feasibility of addressing previously intractable genetic targets. As a result, translational pipelines have broadened to include gene correction, cell engineering, and trait improvement in crops and livestock, while industrial processes have begun to leverage edited organisms for higher-value biomanufacturing.

Consequently, the ecosystem now spans academic laboratories, contract research organizations, biotechnology firms, and large pharmaceutical companies. Each stakeholder group demands differentiated evidence: bench-level validation for researchers, scalable manufacturing approaches for industry, and regulatory and reimbursement intelligence for commercial development. Thus, an integrated synthesis of technological capabilities, application-specific constraints, and regulatory context is essential for informed decision-making.

Moreover, geopolitical and trade dynamics have introduced new variables into supply chains and capital allocation. These external pressures interact with technical progress to influence where and how genome editing innovations are developed, tested, and commercialized. Therefore, readers should expect a holistic assessment that connects scientific trajectories with policy shifts and market-relevant operational considerations.

An in-depth synthesis of scientific, regulatory, and operational shifts that are redefining priorities and value creation across the genome editing landscape

The landscape of genome editing is undergoing multiple transformative shifts that are reshaping research priorities and commercial strategies. First, precision and safety improvements in editing platforms have altered risk-benefit calculations across therapeutic and agricultural applications, prompting a move from exploratory research toward translational and clinical programs. This transition has elevated the importance of delivery technologies and payload optimization as critical enablers of clinical viability.

Second, modularity and interoperability of editing systems are accelerating innovation cycles. Platforms such as base editors, prime editors, and CRISPR-focused nucleases can be combined with evolving delivery vehicles to create tailored solutions for diverse targets, thereby enabling a wider set of stakeholders to pursue differentiated value propositions. Consequently, cross-disciplinary collaboration between molecular biologists, delivery specialists, and process engineers is increasing.

Third, regulatory frameworks are adapting, with agencies worldwide refining guidance on safety assessments, off-target evaluation, and long-term follow-up requirements. These regulatory refinements are influencing development timelines and evidentiary needs, while also opening pathways for earlier dialog between developers and regulators. Simultaneously, heightened public and investor scrutiny places a premium on transparent safety data and robust patient engagement strategies.

Finally, macroeconomic and trade factors are prompting organizations to reassess supply chains, reagent sourcing, and manufacturing footprints. In response, firms are diversifying vendor relationships and investing in regional capabilities to mitigate exposure to external shocks. Taken together, these shifts demand agile strategies that integrate scientific foresight with pragmatic operational planning.

A rigorous analysis of how 2025 tariff measures have reshaped supply chains, procurement strategies, and operational decision-making across the genome editing value chain

Policy shifts in tariff regimes and cross-border trade have material implications for the genome editing ecosystem, affecting reagent flows, instrument imports, and the cost base of downstream manufacturing. Cumulative tariffs imposed in 2025 have amplified the importance of supply chain resilience and vendor diversification, as companies experienced increased lead times and higher landed costs for critical inputs such as enzymes, nucleic acid synthesis services, and specialized laboratory equipment.

As a result, organizations have accelerated localization efforts and sought alternative suppliers with regional capacity. In parallel, procurement teams have adopted multi-sourcing strategies and longer-term contracting to stabilize supply and price exposure. These adjustments have influenced project sequencing and capital allocation decisions, particularly for firms managing clinical pipelines with tight timelines.

Moreover, tariff-driven cost pressures have shifted negotiation dynamics between manufacturers of instruments and reagents and their downstream customers. Some suppliers responded by offering bundled services, flexible financing, or on-shore assembly options to maintain competitiveness. From a strategic perspective, these developments have increased the appeal of vertically integrated models and in-house manufacturing capabilities for larger institutions seeking to control critical production steps.

In addition, tariff impacts have varied across applications and end users, with academic institutes and smaller developers often more exposed to immediate cost increases than well-capitalized pharmaceutical partners. Consequently, collaborative procurement consortia and shared core facilities have emerged as pragmatic responses, allowing multiple organizations to spread fixed costs and maintain access to key technologies despite tariff-related disruptions.

A strategic segmentation framework that dissects technology, application, end-user, therapeutic area, and delivery method to reveal actionable program and investment implications

Segmentation provides the analytical scaffolding needed to translate scientific nuance into commercial insight. When analyzed by technology, the market includes Base Editing with its Adenine Base Editor and Cytosine Base Editor subtypes, CRISPR systems further differentiated into Cas12, Cas13, and Cas9 variants, Prime Editing, Megatal, TALEN, and ZFN, each presenting distinct technical trade-offs in precision, payload constraints, and off-target profiles. This granularity is critical because platform attributes determine downstream choices in delivery, target selection, and safety testing, thereby influencing the types of indications and program designs that are feasible.

When framed by application, key trajectories emerge across Agricultural applications focused on Crop Improvement and Livestock Improvement, Industrial Biotechnology use cases such as Biofuels and Biomanufacturing, Research applications that span Basic Research and Drug Discovery, and Therapeutics encompassing Cell Therapy and Gene Therapy. These application segments require different evidence bases, with agricultural and industrial players prioritizing trait stability and scale, while therapeutic developers emphasize clinical safety, efficacy, and regulatory alignment.

In terms of end users, the ecosystem spans Academic Institutes, Contract Research Organizations, and Pharmaceutical and Biotechnology companies, each with distinct operational models, funding cycles, and access to scale-up capabilities. Academic centers often act as innovation hubs and early proof-of-concept generators, CROs provide specialized expertise and scalable execution, and pharmaceutical and biotech firms focus on commercial development and regulatory pathways.

Therapeutic area segmentation identifies priority domains including Cardiology, Genetic Disorders, Infectious Diseases, Neurology, and Oncology, which differ markedly in biological complexity, patient populations, and clinical trial design considerations. Delivery method segmentation further clarifies feasibility: Nonviral approaches such as Electroporation and Lipid Nanoparticles offer transient expression profiles and reduced immunogenicity risks, Physical Methods like Gene Gun and Microinjection enable ex vivo manipulation or localized delivery, and Viral Vector strategies remain essential for durable in vivo expression. Understanding how these segmentation lenses intersect enables stakeholders to align platform selection with target indications and development strategies.

A comparative regional analysis highlighting how distinct regulatory environments, manufacturing capabilities, and research ecosystems shape genome editing strategies across global markets

Regional dynamics exert a decisive influence on technology adoption, regulatory strategy, and partnership models. In the Americas, strong venture capital activity, a concentration of clinical trial infrastructure, and a dense network of translational research centers have supported rapid progression of novel editing therapies from discovery into early clinical development. These regional strengths make the Americas a focal point for collaborative scientific networks and sizable biotech clusters that accelerate translational momentum.

In Europe, the Middle East & Africa region, regulatory harmonization across multiple jurisdictions and a diverse payer landscape shape development tactics. European research institutions continue to contribute foundational scientific advances while startups and larger pharmaceutical firms navigate complex reimbursement and ethical frameworks. Meanwhile, investments in manufacturing capacity and strategic public-private partnerships are emerging as levers to maintain competitiveness in advanced therapies.

In the Asia-Pacific, rapid scaling of manufacturing capability, a growing base of skilled scientists, and proactive government initiatives to support biotechnology innovation have led to expanding research and commercialization pathways. Additionally, regional differences in regulatory timelines and clinical trial enrollment dynamics have encouraged multinational developers to adopt flexible clinical strategies that leverage Asia-Pacific strengths for expedited patient recruitment and cost-efficient development.

Across these regions, stakeholders increasingly adopt hybrid strategies that combine local capabilities with cross-border partnerships, thereby optimizing access to talent, capital, and patient populations while managing regional regulatory and supply chain variability.

A clear-eyed examination of company strategies across platform innovators, therapeutic developers, service providers, and manufacturing specialists that drive competitive positioning

Company-level dynamics in genome editing reflect a spectrum of archetypes ranging from platform technology pioneers to vertically integrated developers and specialized service providers. Platform-focused firms concentrate on improving editing specificity, expanding target scope, and creating modular systems that can be licensed or partnered into diverse application areas. These organizations typically invest heavily in R&D to maintain lead positions in core technologies such as base editing, prime editing, and nuclease optimization.

Therapeutic developers often follow licensing and collaboration pathways to combine platform strengths with clinical and regulatory expertise, thereby accelerating the translation of early-stage discoveries into clinical candidates. Service providers and contract research organizations have adapted by bundling end-to-end capabilities that include target validation, delivery optimization, and GLP-compliant safety testing, creating turnkey solutions for sponsors seeking to outsource technical complexity.

Manufacturing and supply chain specialists are also evolving to support advanced therapy production, with investments in scalable fill-finish, vector production, and quality systems. In addition, there is a growing emphasis on strategic partnerships that align platform owners with manufacturing specialists and commercial partners to de-risk late-stage development and enable broader market access. Collectively, these company-level strategies illustrate how ecosystem participants position themselves to capture value at different points in the innovation-to-commercialization continuum.

Action-oriented strategic guidance for executives to align technology development, partnerships, regulatory engagement, and operational resilience for sustainable growth

Industry leaders must adopt multifaceted, pragmatic strategies to convert technological promise into commercial success. First, investing in delivery innovation and payload engineering is essential, because improvements in how editing systems reach target cells and tissues materially affect clinical feasibility and agricultural application outcomes. Companies should prioritize integration between editing chemistry and delivery modality early in program design to reduce downstream development risk.

Second, leaders should pursue flexible partnership models that balance proprietary control with the practical benefits of collaboration. Strategic alliances with specialized contract research organizations, manufacturing partners, and regional development hubs can accelerate time to clinic while preserving optionality for commercialization. In parallel, developing a robust regulatory affairs capability and engaging regulators early in development can smooth approval pathways and define acceptable safety endpoints.

Third, operational resilience must be elevated through supply chain diversification, regional manufacturing planning, and long-term supplier agreements. These measures mitigate exposure to trade disruptions and ensure continuity of clinical and commercial programs. Moreover, companies should strengthen data governance and ethical oversight frameworks to sustain public trust and meet evolving societal expectations.

Finally, firms should align investment decisions with clear go-to-market strategies that consider therapeutic area complexity, patient recruitment dynamics, and reimbursement scenarios. By matching platform strengths to indications where scientific rationale, regulatory feasibility, and commercial upside converge, leaders can prioritize programs with the highest prospective impact and resource efficiency.

A transparent and rigorous mixed-methods research approach that integrates expert interviews, technical literature synthesis, and scenario-based analysis to validate findings

The research methodology combines primary and secondary qualitative techniques with rigorous evidence synthesis to deliver robust insights into the genome editing ecosystem. Primary research includes structured interviews with domain experts across academic institutions, contract research organizations, biotechnology developers, and therapeutic sponsors. These dialogues provide context on practical constraints, development timelines, and strategic priorities that are not always evident in public literature.

Secondary research synthesizes peer-reviewed publications, regulatory guidance documents, patent filings, and corporate disclosures to construct a comprehensive technical and policy narrative. Where appropriate, technical white papers, conference proceedings, and preprint literature were reviewed to capture the most recent advances in editing platforms and delivery systems. Triangulation across these sources ensures that conclusions are grounded in reproducible evidence and expert validation.

Analytical frameworks employed in the study include technology readiness assessments, value-chain mapping, and scenario-based risk analysis. Sensitivity checks were performed through iterative expert review, and findings were validated through cross-sector workshops to ensure relevance to both R&D and commercial stakeholders. Confidentiality protocols were applied to primary interviews to protect proprietary inputs and encourage candid commentary.

A concise synthesis that connects technical innovation with regulatory, ethical, and operational imperatives to guide decision-makers toward impactful programs

The trajectory of genome editing is characterized by converging forces: technical refinement of editing chemistries, maturation of delivery approaches, evolving regulatory expectations, and shifting economic pressures. Together, these forces create a dynamic environment in which strategic agility, technical excellence, and operational robustness determine which programs progress successfully from concept to impact. As stakeholders navigate this environment, they will need to make disciplined choices about platform focus, partnership structures, and geographic deployment.

Importantly, the most promising near-term opportunities are those that effectively pair technical feasibility with clear translational pathways, whether in therapeutics, agriculture, or industrial biotechnology. Concurrently, managing supply chain exposure and investing in compliance and ethical governance will be critical to sustaining long-term momentum. By synthesizing technological, regulatory, and commercial considerations, organizations can prioritize initiatives with the highest potential to deliver meaningful scientific and societal benefits.

Ultimately, success in genome editing will be defined not only by scientific breakthroughs but by the capacity of organizations to operationalize those breakthroughs at scale, responsibly and resiliently.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in base and prime editing technologies for precise single-nucleotide modifications
  • 5.2. Integration of AI-driven bioinformatics platforms in guiding CRISPR target selection
  • 5.3. Development of nonviral delivery systems for in vivo genome editing therapies
  • 5.4. Regulatory harmonization efforts for global approval of gene editing therapeutics
  • 5.5. Ethical and societal challenges surrounding germline genome editing applications
  • 5.6. Expansion of CRISPR diagnostics in rapid infectious disease detection and surveillance
  • 5.7. Commercialization of gene edited cell therapies for hematological disorders and cancers
  • 5.8. Growth of insect gene drive projects for vector-borne disease control and ecological risk assessment
  • 5.9. Emergence of anti-CRISPR proteins as safety switches in genome editing protocols
  • 5.10. Advances in multiplex genome editing for engineering complex genetic circuits in cells
  • 5.11. Strategic partnerships between biopharma and tech companies to accelerate genome editing research
  • 5.12. Patent landscape shifts after recent Supreme Court rulings on CRISPR intellectual property

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genome Editing Market, by Technology

  • 8.1. Base Editing
    • 8.1.1. Adenine Base Editor
    • 8.1.2. Cytosine Base Editor
  • 8.2. Crispr
    • 8.2.1. Cas12
    • 8.2.2. Cas13
    • 8.2.3. Cas9
  • 8.3. Megatal
  • 8.4. Prime Editing
  • 8.5. Talen
  • 8.6. Zfn

9. Genome Editing Market, by Application

  • 9.1. Agricultural
    • 9.1.1. Crop Improvement
    • 9.1.2. Livestock Improvement
  • 9.2. Industrial Biotechnology
    • 9.2.1. Biofuels
    • 9.2.2. Biomanufacturing
  • 9.3. Research
    • 9.3.1. Basic Research
    • 9.3.2. Drug Discovery
  • 9.4. Therapeutics
    • 9.4.1. Cell Therapy
    • 9.4.2. Gene Therapy

10. Genome Editing Market, by End User

  • 10.1. Academic Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Pharmaceutical Biotech

11. Genome Editing Market, by Therapeutic Area

  • 11.1. Cardiology
  • 11.2. Genetic Disorders
  • 11.3. Infectious Diseases
  • 11.4. Neurology
  • 11.5. Oncology

12. Genome Editing Market, by Delivery Method

  • 12.1. Nonviral
    • 12.1.1. Electroporation
    • 12.1.2. Lipid Nanoparticles
  • 12.2. Physical Methods
    • 12.2.1. Gene Gun
    • 12.2.2. Microinjection
  • 12.3. Viral Vector

13. Genome Editing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Genome Editing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Genome Editing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Danaher Corporation
    • 16.3.3. Merck KGaA
    • 16.3.4. Agilent Technologies, Inc.
    • 16.3.5. Lonza Group AG
    • 16.3.6. Sartorius AG
    • 16.3.7. Becton Dickinson and Company
    • 16.3.8. CRISPR Therapeutics AG
    • 16.3.9. Intellia Therapeutics, Inc.
    • 16.3.10. Sangamo Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENOME EDITING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GENOME EDITING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GENOME EDITING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GENOME EDITING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GENOME EDITING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GENOME EDITING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GENOME EDITING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GENOME EDITING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL GENOME EDITING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL GENOME EDITING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS GENOME EDITING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS GENOME EDITING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS GENOME EDITING MARKET SIZE, BY BASE EDITING, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS GENOME EDITING MARKET SIZE, BY CRISPR, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS GENOME EDITING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS GENOME EDITING MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS GENOME EDITING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS GENOME EDITING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS GENOME EDITING MARKET SIZE, BY NONVIRAL, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA GENOME EDITING MARKET SIZE, BY CRISPR, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA GENOME EDITING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA GENOME EDITING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA GENOME EDITING MARKET SIZE, BY CRISPR, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 331. LATIN AMERICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 332. LATIN AMERICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 333. LATIN AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 334. LATIN AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 335. LATIN AMERICA GENOME EDITING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. LATIN AMERICA GENOME EDITING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. LATIN AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 338. LATIN AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 339. LATIN AMERICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 340. LATIN AMERICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 341. LATIN AMERICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2024 (USD MILLION)
  • TABLE 342. LATIN AMERICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2025-2032 (USD MILLION)
  • TABLE 343. LATIN AMERICA GENOME EDITING MARKET SIZE, BY PHYSICAL ME